BEAM

Beam Therapeutics Inc. (BEAM)

NASDAQ
$25.75
$+0.77
(+3.11%)
Beam Therapeutics Inc. (BEAM) Live Price Chart
Page last updated: 2026-02-06 15:33:00

Key Market Data

$2.61B

$25.63

$138.52

$13.00

$24.73

$+0.77

+3.11%

250K

Beam Therapeutics Inc. (BEAM) Stock Price Today

Beam Therapeutics Inc. (BEAM) is currently trading at $25.75 as of 2026-02-06 15:33:00, reflecting a +3.11% move ($+0.77) from the previous close.

In the short term, the stock has returned -805.36% over the past four weeks. Over the last 12 months, Beam Therapeutics Inc. has recorded a -6.89% price change, indicating a weak performance relative to the broader market.

Beam Therapeutics Inc. (BEAM) 7-Day Stock Price Changes

Over the past seven days, Beam Therapeutics Inc. has traded within a short-term range shaped by market sentiment in the BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) sector. During this period, the stock moved from its previous closing price of $27.51 to the latest recorded price of $25.75, reflecting an intraday change of +3.11%. Daily movements highlight shifts in trading volume (249,894), investor positioning, and reactions to macroeconomic updates.

From a momentum standpoint, BEAM has delivered a -805.36% return over the past month and a -6.89% change in the last 12 months, indicating a weak trend relative to its broader sector peers.

How to Buy Beam Therapeutics Inc. (BEAM)

You can buy and trade BEAM on MEXC in three simple steps:

Step 1: Create and Verify Your MEXC Account
Step 1: Create and Verify Your MEXC Account
Sign up on MEXC and complete the required identity verification (KYC). This ensures full access to trading features and secure funding options.
Step 2: Deposit Funds Into Your Account
Step 2: Deposit Funds Into Your Account
Choose your preferred payment method to add USDT or other supported assets to your MEXC wallet. Depositing crypto is the fastest way to get started.
Step 3: Search for BEAM and Execute Your Trade
Step 3: Search for BEAM and Execute Your Trade
Open the trading page, enter BEAM in the search bar, select the amount of BEAM you would like to purchase. Place a market order for instant execution or a limit order to buy at your target price.

What is Beam Therapeutics Inc. (BEAM)?

Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.

Beam Therapeutics Inc. Information

Industry
BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Employees
510
Sector
BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Company Website

Frequently Asked Questions (FAQ)

1.What is the current share price of Beam Therapeutics Inc.?
The latest trading price for Beam Therapeutics Inc. (Common Stock) is $ 25.75, compared with a previous closing price of $ 24.73. That means the stock has moved +3.11% so far today. Intraday price updates and recent trading activity for BEAM can be tracked on the live chart and quote section on this page.
2.Is Beam Therapeutics Inc. stock going up or down?
Looking at recent performances, BEAM has returned -805.36% over the past month, +49.99% over the last six months and -6.89% over the past year. These figures capture share-price changes only, not the impact of dividends. Together they describe weak price momentum for Beam Therapeutics Inc. stock, but keep in mind that past returns do not guarantee future results.
3.Where does BEAM currently sit relative to its 52-week high and low?
In the most recent 52-week period, Beam Therapeutics Inc. has traded between a low of $ 13.53 and a high of $ 36.44. This 52-week range helps show where today's share price sits relative to its recent highs and lows, and is often used by investors to judge stock volatility, potential support and resistance levels, and whether BEAM is currently nearer the top or the bottom of its one-year trading band.
4.How is Beam Therapeutics Inc. classified by sector and industry?
Beam Therapeutics Inc. is classified in the BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) sector, within the BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry group and the BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry. In practice, this means Beam Therapeutics Inc. is grouped with companies that face similar end-markets, competitive dynamics and regulatory environments. For investors, knowing BEAM's sector and industry classification helps when building diversified portfolios, comparing Beam Therapeutics Inc. with direct peers, and understanding how stock-specific risks such as -- may be influenced by broader trends in the BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) sector and BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry.
5.Where is Beam Therapeutics Inc. listed and how large is it by market value?
Beam Therapeutics Inc. is listed on the NASDAQ stock exchange in United States. Based on a market capitalization of $ 2.61B, the company is classified as a Mid-cap stock. Market cap gives a quick sense of Beam Therapeutics Inc.'s size and importance in the equity market and is often used by investors and index providers when constructing portfolios or benchmarks.
6.What does BEAM's EPS tell investors about its profitability?
Trailing-twelve-month EPS of $ -4.09 summarises how much profit Beam Therapeutics Inc. has generated per share over the last year. Rising EPS over time can signal improving profitability or effective share repurchases, while flat or declining EPS may point to slower growth or margin pressure. EPS is a key input into valuation metrics such as P/E and is often monitored closely around earnings announcements.
7.How can I track Beam Therapeutics Inc.'s financial performance over time?
To follow Beam Therapeutics Inc.'s financial performance, investors typically review its quarterly and annual reports, which include detailed income statements, balance sheets and cash-flow statements. Combining these filings with key market data shown on this page—such as share price trends, P/E and dividend yield—provides a more complete view of how BEAM is performing and how the market is responding.
8.When is Beam Therapeutics Inc. expected to report earnings?
Beam Therapeutics Inc.'s next scheduled earnings release is currently expected on -- (the date may be updated by the company). Earnings announcements often act as important catalysts for BEAM, as they provide updated information on revenue, profitability and management's outlook.
9.What usually comes out in Beam Therapeutics Inc.'s earnings reports?
Beam Therapeutics Inc.'s earnings reports typically include headline figures such as revenue, net income and EPS, along with commentary on segment performance, margins, cash flow and guidance for future periods. Investors compare these results with market expectations and prior periods to assess whether BEAM is meeting, beating or missing expectations.
10.How can I stay informed about Beam Therapeutics Inc.'s results and guidance?
You can stay up to date on Beam Therapeutics Inc. by reviewing its quarterly earnings releases, listening to or reading transcripts of earnings calls, and following company news and filings. Pairing this fundamental information with the price and return data for BEAM on this page helps you see how new information is being reflected in the stock.
11.Does Beam Therapeutics Inc. pay a regular cash dividend to its shareholders?
Beam Therapeutics Inc. Non-paying. Based on the latest information, the stock has an indicated annual cash dividend of -- per share and a current dividend yield of 0 at the recent share price. Dividends are typically paid --, although the board can change the dividend policy at any time. Income-focused investors often monitor BEAM's dividend level, payment frequency and any announcements about future dividends when assessing the stock's appeal as a dividend-paying investment.
12.What are the current dividend yield and dividend payout ratio for BEAM?
Based on the latest earnings data, BEAM has a dividend yield of 0 and a dividend payout ratio of 0. The dividend yield shows how much cash return an investor receives from dividends each year relative to the current share price, helping assess whether Beam Therapeutics Inc. is an attractive income stock. The dividend payout ratio measures what percentage of earnings Beam Therapeutics Inc. distributes to shareholders as dividends versus how much it retains to reinvest in the business, which is an important indicator of dividend sustainability and room for future dividend growth.
13.What kind of business is Beam Therapeutics Inc.?
Beam Therapeutics Inc. is a publicly traded company in the BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry within the BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) sector. It generates revenue from products and services related to this core business area, and investors can find a detailed description of its operations, strategy and geographic exposure in the company's annual report and other regulatory filings.
14.How is BEAM valued in terms of P/E ratio and EPS?
Beam Therapeutics Inc. currently trades at a price-to-earnings (P/E) ratio of --, based on trailing-twelve-month earnings per share (EPS) of $ -4.09. P/E is calculated by dividing the share price by EPS and shows how much investors are paying today for each unit of Beam Therapeutics Inc.'s earnings. Comparing BEAM's P/E and EPS to those of other BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) companies can help investors judge whether its valuation looks rich or attractive.

Explore More US Stocks

Stocks in the Same Sector

Browse other US stocks in the same sector as Beam Therapeutics Inc.

Largest Market Cap

See US stocks with the highest market capitalization

Top 5 Cryptocurrencies

Explore the cryptocurrencies with the highest market capitalization

Disclaimer

The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.

BEAM-to-USD Calculator

Amount

BEAM
BEAM
USD
USD

1 BEAM = 25.745 USD